Progyny将2025年EPS预测值提高到1.79美元至1.82美元,尽管销售量减少,Q4收入出现亏损,但利润率仍然很高。 Progyny raised 2025 EPS forecast to $1.79–$1.82, citing strong margins despite lower sales volume and a Q4 earnings miss.

Progyny(PGNY)将其2025年全年EPS指南提高到1.79美元至1.82美元(超出预期),并预测Q4 EPS为0.37美元至0.40美元,尽管其实际Q4收入为每股0.15美元。 Progyny (PGNY) raised its full-year 2025 EPS guidance to $1.79–$1.82, exceeding expectations, and projected Q4 EPS of $0.37–$0.40, though its actual Q4 earnings of $0.15 per share missed estimates. 根据预测,该年度的收入指导定为13亿美元。 Revenue guidance for the year was set at $1.3 billion, in line with forecasts. 该公司向美国雇主提供生育福利,它报告说,尽管销售量急剧下降,但由于价格的驱动,它仍大力调整了EBITDA,提高了营业利润率。 The company, which provides fertility benefits to U.S. employers, reported strong adjusted EBITDA and improved operating margins, driven by pricing despite a sharp drop in sales volumes. 分析师保持“机动购买”评级,平均价格目标为25.44美元,而机构所有权仍然很高,为94.93%。 Analysts maintain a "Moderate Buy" rating, with a $25.44 average price target, while institutional ownership remains high at 94.93%.